icon-folder.gif   Conference Reports for NATAP  
 
  HIV Drug Therapy Glasgow 2024
10-13 November
Back grey_arrow_rt.gif
 
 
 
Annual persistence in use of twice-yearly lenacapavir
versus daily oral PrEP in the PURPOSE 1 phase 3 trial
 
 
 

1209241

1209242

1209243

1209243

1209244

1209245

1209246

1209247